| Clinical Trial Name | Clinical Trial Full Title | Principal Investigator | Project site status | Clinical trials gov number |
|---|---|---|---|---|
| (CCTG) BL.13 | A Randomized Phase II Trial Assessing Trimodality Therapy With or Without Adjuvant Durvalumab (MEDI4736) to Treat Patients with Muscle-Invasive Bladder Cancer | Lalani, Dr Aly-Khan | Open to recruitment | NCT03768570 |
| (CCTG) IND.234 / PC-BETS - Master Protocol | Prostate Cancer Biomarker Enrichment and Treatment Selection (PC_BETS) Study - Master Screening Protocol | Mukherjee, Dr Som | Open to recruitment | NCT03385655 (Master) |
| (CCTG) IND.234B/PC-BETS Sub-Study B | A Phase II Study of Savolitinib, A CMET Inhibitor, in Patients with Metastatic Castration-Resistant Prostate Cancer - A Sub-Study of IND.234 | Mukherjee, Dr Som | Open to recruitment | NCT03385655(B) |
| (CCTG) IND.234C/PC-BETS Sub-Study C | A Phase II Study of Darolutamide (ODM-201) in Patients with Metastatic Castration-Resistant Prostate Cancer Previously Treated with Abiraterone Acetate or Enzalutamide - A Sub-Study of IND.234 | Mukherjee, Dr Som | Open to recruitment | NCT03385655(C) |
| (CCTG) IND.234D/PC-BETS Sub-Study D | A Phase II Study of CFI-400945 Fumarate in Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Mukherjee, Dr Som | Open to recruitment | NCT03385655(D) |
| (CCTG) IND.234E/PC-BETS Sub-Study E | A Phase II Study of Ipatasertib in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients with PI3K Pathway Alterations in Circulating Tumour DNA (ctDNA) | Mukherjee, Dr Som | Open to recruitment | NCT03385655(E) |
| (CCTG) IND.234F/PC-BETS Sub-Study F | A Phase II Study of Durvalumab and Tremelimumab in Metastatic Castration-Resistant Prostate Cancer | Mukherjee, Dr Som | Open to recruitment | NCT03385655 (F) |
| (CCTG) IND.234G/PC-BETS Sub-Study G | A Phase II Study of Carboplatin in Patients with Metastatic Castration-Resistant Prostate Cancer | Mukherjee, Dr Som | Open to recruitment | NCT03385655 (G) |
| (CCTG) PR.20 | A Randomized Phase III Trial of Local Ablative Therapy For Hormone Sensitive Oligometastatic Prostate Cancer (PLATON) | Quan, Dr Kimmen | Open to recruitment | NCT03784755 |
| (CHUM) 20.208 / PATRON | PSMA PET/CT Guided Intensification of Therapy in Patients at Risk of Advanced Prostate Cancer | Tsakiridis, Dr Theos | Open to recruitment | NCT04557501 |
| (EXELIXIS) XL184-315 / CONTACT-02 | A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL 184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy(NHT) in Subjects with High-Risk, Metastatic Castration-Resistant Prostate Cancer. | Hotte, Dr Sebastien | Open to recruitment | NCT04446117 |
| (Immunomedics) TROPICS-04 / IMMU-132-13 | A RANDOMIZED OPEN-LABEL PHASE III STUDY OF SACITUZUMAB GOVITECAN VERSUS TREATMENT OF PHYSICIAN’S CHOICE IN SUBJECTS WITH METASTATIC OR LOCALLY ADVANCED UNRESECTABLE UROTHELIAL CANCER | Mukherjee, Dr Som | Open to recruitment | NCT04527991 |
| (JCC) The PBS Study | A randomized phase II trial investigating Stereotactic Body RadioTherapy (SBRT) for prostate boost irradiation in the treatment of high risk Prostate Cancer (PrCa) | Tsakiridis, Dr Theos | Open to recruitment | NCT03380806 |
| (Merck) MK-6482-012 | A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012) | Lalani, Dr Aly-Khan | Open to recruitment | NCT04736706 |
| (OHRI) RADIANT/OTT-19-07/OZM-105 | Neoadjuvant Immune-Modulating Radiation with Durvalumab (MEDI 4736) prior to Radical Cystectomy in Patients With Muscle-Invasive Bladder Carcinoma (RADIANT) | Lalani, Dr Aly-Khan | Open to recruitment | NCT04543110 |
| (Seattle Genetics) SGN22E-003 / EV-302 | An open-label, randomized, controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab versus chemotherapy alone in previously untreated locally advanced or metastatic urothelial cancer | Hotte, Dr Sebastien | Open to recruitment | NCT04223856 |
| (SHSC) AQuOS-II | Assessment of Quality of Life and Outcomes in Patients Treated With Stereotactic Body Radiotherapy (SBRT) for Inoperable Renal Cell Carcinoma (RCC): A Multicenter Phase II Study | Swaminath, Dr Anand | Open to recruitment | NCT05023265 |
| (UHN) WI222910 / ALPACA | A Phase 2, Multi-centre, Open-label Study of Avelumab (MSB0010718C) in Locally Advanced or Metastatic Penile Cancer Patients Unfit for Platinum-based Chemotherapy or Progressed On or After Platinum-based Chemotherapy | Mukherjee, Dr Som | Open to recruitment | NCT03391479 |
| OCOG-2019-CYTOSHRINK / CA209-7DR | Cytoreductive Stereotactic Hypofractionated Radiotherapy With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer | Lalani, Dr Aly-Khan | Open to recruitment | NCT04090710 |
| (ESSA Pharma) EPI-7386-CS-010 | A Phase 1/2 Study of EPI-7386 in Combination with Enzalutamide Compared with Enzalutamide Alone in Subjects with Metastatic Castration-Resistant Prostate Cancer | Hotte, Dr Sebastien | Suspended/On hold | NCT05075577 |
| (JGH) PCS IX / PCS 9 | The Role of Stereotactic Body Radiotherapy in the Management of Castration-Resistant Prostate Cancer With Oligometastases: An Adaptive Phase II/III Randomized Trial. | Tsakiridis, Dr Theos | Suspended/On hold | NCT02685397 |
| (Merck) MK-6482-011 / LiteSpark011 | An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy | Lalani, Dr Aly-Khan | Suspended/On hold | NCT04586231 |
Find a Trial
Contact Us